All 2 tracked stories fall under one category: regulation. Viagra is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. They are better corroborated than the beat average, carrying 26.5 original sources each against 5.1 for the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Sildenafil
All 2 tracked stories fall under one category: regulation. Viagra is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. They are better corroborated than the beat average, carrying 26.5 original sources each against 5.1 for the same window. At 6, the average consequence score sits below the same-window beat average of 6.1. We currently track 2 Healthcare stories that mention Sildenafil, all published on March 13, 2026.
Stories tracked
2
Sources per story
26.5
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 27 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Sildenafil. Shared-story counts are live from our verified record — not editorial picks.
A nationwide recall has been issued for a wellness supplement following the discovery of sildenafil, the active ingredient in the prescription drug Viagra. The presence of this undeclared pharmaceutical poses severe health risks, particularly through potentially fatal interactions with common heart medications.
A widespread recall has been issued for a wellness supplement after laboratory testing confirmed the presence of sildenafil, the active pharmaceutical ingredient in Viagra. The discovery highlights critical gaps in the regulation of over-the-counter 'natural' products and poses severe risks to consumers with underlying cardiovascular conditions.